Oncolytics Biotech (ONCY) Other Non-Current Liabilities (2009 - 2022)
Oncolytics Biotech (ONCY) posted quarterly Other Non-Current Liabilities of $2.9 million for Q1 2022, little changed year-over-year from $2.9 million in Q1 2021, and little changed quarter-over-quarter from $2.9 million in Q4 2021.
Oncolytics Biotech (ONCY) Other Non-Current Liabilities (2009 - 2022) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Other Non-Current Liabilities for 11 consecutive years, with $2.9 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Other Non-Current Liabilities changed 0.08% year-over-year to $2.9 million; the TTM figure through Mar 2022 stood at $2.9 million (changed 0.08% YoY), while the FY2021 annual figure was $2.9 million, up 6.91% from the prior year.
- Other Non-Current Liabilities steadied at $2.9 million in Q1 2022 per ONCY's latest filing, from $2.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.6 million in Q1 2018 and bottomed at $39720.5 in Q4 2018.
- Historically, Other Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $3.6 million in 2018.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities tumbled 100.0% — and 2019, when it jumped 6798.97%.
- Oncolytics Biotech's Other Non-Current Liabilities stood at $39720.5 in 2018, then surged by 6798.97% to $2.7 million in 2019, then increased by 1.26% to $2.8 million in 2020, then grew by 3.44% to $2.9 million in 2021, then decreased by 0.5% to $2.9 million in 2022.
- Business Quant data shows ONCY's Other Non-Current Liabilities at $2.9 million in Q1 2022, $2.9 million in Q4 2021, and $2.9 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 2.86 Mn |
| Dec 31, 2021 | 2.87 Mn |
| Sep 30, 2021 | 2.87 Mn |
| Jun 30, 2021 | 2.94 Mn |
| Mar 31, 2021 | 2.86 Mn |
| Dec 31, 2020 | 2.77 Mn |
| Sep 30, 2020 | 3.62 Mn |
| Jun 30, 2020 | 3.62 Mn |
| Mar 31, 2020 | 3.62 Mn |
| Dec 31, 2019 | 2.74 Mn |
| Sep 30, 2019 | 3.62 Mn |
| Jun 30, 2019 | 3.62 Mn |
| Mar 31, 2019 | 3.62 Mn |
| Dec 31, 2018 | 39,720.49 |
| Sep 30, 2018 | 3.62 Mn |
| Jun 30, 2018 | 3.62 Mn |
| Mar 31, 2018 | 3.62 Mn |
| Sep 30, 2017 | 3,617.90 Bn |
| Jun 30, 2017 | 3.62 Mn |
| Dec 31, 2013 | 376,892.00 |